📊 RIGL Key Takeaways
Is Rigel Pharmaceuticals Inc. (RIGL) a Good Investment?
Strong revenue growth of 64% is undermined by flat net income and severely weak free cash flow conversion ($2.3M FCF on $58.8M revenue), indicating structural profitability challenges. The 2.2% ROE and 1.7% ROA reveal poor capital efficiency, suggesting revenue growth is not translating into shareholder value creation.
Rigel shows strong top-line growth and solid free cash flow alongside low leverage and ample liquidity. Yet the extraordinary operating and net margins appear driven by non-recurring items, with a very low 5.9% gross margin indicating weak underlying unit economics. Sustained improvements in recurring margins and cash conversion are needed to validate durability of earnings.
Why Buy Rigel Pharmaceuticals Inc. Stock? RIGL Key Strengths
- Robust revenue growth of 64.1% year-over-year demonstrates market traction
- Healthy operating margin (20.2%) and net margin (14.7%) provide profitability foundation
- Strong liquidity with current ratio 2.62x and conservative balance sheet with Debt/Equity of 0.11x
- 64% YoY revenue growth
- Healthy free cash flow (25.6% margin) with minimal capex
- Strong liquidity (2.42x current) and low leverage (0.13x D/E)
RIGL Stock Risks: Rigel Pharmaceuticals Inc. Investment Risks
- Net income stagnation (0% growth) despite strong revenue growth signals margin compression or rising operating costs
- Critical cash conversion gap: $8.7M net income but only $2.7M operating cash flow suggests earnings quality concerns
- Abysmal return metrics (2.2% ROE, 1.7% ROA) indicate capital is deployed inefficiently with minimal value generation
- Earnings quality: profits inflated by one-off/non-operating items
- Very low gross margin (5.9%) suggests weak unit economics
- Revenue mix/product concentration and regulatory risks typical for biotech
Key Metrics to Watch
- Operating cash flow trend and reconciliation with net income divergence
- Explanation for net income stagnation despite 64% revenue growth
- ROE and ROA trajectory improvement and free cash flow margin expansion
- Gross margin and product vs milestone/collaboration mix
- Operating cash flow consistency vs net income
Rigel Pharmaceuticals Inc. (RIGL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.9% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.62x current ratio provides a solid financial cushion.
RIGL Profit Margin, ROE & Profitability Analysis
RIGL vs Healthcare Sector: How Rigel Pharmaceuticals Inc. Compares
How Rigel Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rigel Pharmaceuticals Inc. Stock Overvalued? RIGL Valuation Analysis 2026
Based on fundamental analysis, Rigel Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rigel Pharmaceuticals Inc. Balance Sheet: RIGL Debt, Cash & Liquidity
RIGL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rigel Pharmaceuticals Inc.'s revenue has grown significantly by 97% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.44 indicates the company is currently unprofitable.
RIGL Revenue Growth, EPS Growth & YoY Performance
RIGL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $53.3M | $8.7M | $0.44 |
| Q3 2025 | $55.3M | $3.1M | $0.18 |
| Q2 2025 | $36.8M | -$1.0M | $-0.06 |
| Q1 2025 | $29.5M | -$8.2M | $-0.47 |
| Q3 2024 | $28.1M | $3.1M | $0.18 |
| Q2 2024 | $26.9M | -$1.0M | $-0.06 |
| Q1 2024 | $26.1M | -$8.2M | $-0.05 |
| Q3 2023 | $22.4M | -$5.7M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rigel Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
RIGL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rigel Pharmaceuticals Inc. (CIK: 0001034842)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RIGL
What is the AI rating for RIGL?
Rigel Pharmaceuticals Inc. (RIGL) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RIGL's key strengths?
Claude: Robust revenue growth of 64.1% year-over-year demonstrates market traction. Healthy operating margin (20.2%) and net margin (14.7%) provide profitability foundation. ChatGPT: 64% YoY revenue growth. Healthy free cash flow (25.6% margin) with minimal capex.
What are the risks of investing in RIGL?
Claude: Net income stagnation (0% growth) despite strong revenue growth signals margin compression or rising operating costs. Critical cash conversion gap: $8.7M net income but only $2.7M operating cash flow suggests earnings quality concerns. ChatGPT: Earnings quality: profits inflated by one-off/non-operating items. Very low gross margin (5.9%) suggests weak unit economics.
What is RIGL's revenue and growth?
Rigel Pharmaceuticals Inc. reported revenue of $58.8M.
Does RIGL pay dividends?
Rigel Pharmaceuticals Inc. does not currently pay dividends.
Where can I find RIGL SEC filings?
Official SEC filings for Rigel Pharmaceuticals Inc. (CIK: 0001034842) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RIGL's EPS?
Rigel Pharmaceuticals Inc. has a diluted EPS of $0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RIGL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Rigel Pharmaceuticals Inc. has a HOLD rating with 66% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RIGL stock overvalued or undervalued?
Valuation metrics for RIGL: ROE of 2.2% (sector avg: 15%), net margin of 14.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RIGL stock in 2026?
Our dual AI analysis gives Rigel Pharmaceuticals Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is RIGL's free cash flow?
Rigel Pharmaceuticals Inc.'s operating cash flow is $2.7M, with capital expenditures of $450.0K. FCF margin is 3.9%.
How does RIGL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 14.7% (avg: 12%), ROE 2.2% (avg: 15%), current ratio 2.62 (avg: 2).